Market Research Industry Reports

Laboratory Corp of America Holdings (LH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics laboratory services such as core testing, genomic and esoteric testing. Its services include general and specialty laboratory testing, ambulatory monitoring services, bone marrow and human leukocyte antigen (HLA) testing, clinical trials services, drug testing services, DNA identification services, forensic identity services, insurance health plan services, paternity testing services, patient services, personalized medicine and hospital services. It also offers drug development services through Covance. It offers its services to managed care organizations, physicians, hospitals, government agencies and biotechnology and pharmaceutical companies through a network of primary laboratories and patient service centers. The company has operations across the US, Columbia, Belgium, Puerto Rico, Japan, China, Singapore, the UK and three Canadian provinces. LabCorp is headquartered in Burlington, North Carolina, the US.

Laboratory Corp of America Holdings (LH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 7
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Laboratory Corp of America Holdings, Medical Devices Deals, 2012 to YTD 2018 12
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
LabCorp Acquires High-Complexity Genomic Lab From Covance 16
LabCorp To Acquire MuirLab Business From John Muir Health 17
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 18
Gamma-Dynacare Medical To Acquire Quebec Operations Of Lifelabs 19
Venture Financing 20
Orig3n Raises USD20 Million in Venture Financing 20
Sera Prognostics Raises USD40 Million in Series C Financing 22
Orig3N Raises USD12.5 Million in Series A Financing 23
Orig3N Raises Funds through Venture Financing 25
Flatiron Health Raises US$130 Million In Series B Financing 26
Private Equity 27
Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million 27
Partnerships 28
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 28
Laboratory Corp Enters into Partnership with Capital Health 29
Emulate Enters into Agreement with Covance 30
Sequenom Enters into Agreement with University of Colorado Denver 31
Motif Bio Enters into Agreement with Covance 32
Sequenom Enters into Agreement with University Medical Center Hamburg 33
Sequenom Enters into Agreement with Seoul National University Hospital 34
Sequenom enters into an Agreement with University of California 35
Covance Enters into Co-Development Agreement with Sihuan Pharma 36
Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 37
Covance Enters into Research Agreement with Frenova Renal Research 38
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 39
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 40
Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 41
GNS Healthcare Enters Into Co-Development Agreement With Covance 42
Bayer HealthCare Enters Into Agreement With Covance 43
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 44
Licensing Agreements 46
LabCorp Enters into Licensing Agreement with Transgenomic 46
Equity Offering 47
Sequenom Completes Public Offering Of Common Stock For US$62 Million 47
Debt Offering 49
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 49
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 51
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 53
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 55
Covance Completes Private Placement Of Notes Due 2025 For US$95 Million 57
Covance Completes Private Placement Of Notes Due 2023 For US$90 Million 58
Covance Completes Private Placement Of Notes Due 2018 For US$15 Million 59
Covance Completes Private Placement Of Notes Due 2020 For US$50 Million 60
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 61
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 63
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 65
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 66
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 68
Asset Transactions 70
LabCorp Acquires High-Complexity Genomic Lab From Covance 70
Marken Acquires European Kit Building Operation Facility From LabCorp 71
Acquisition 72
LabCorp Acquires Chiltern International for USD1.2 Billion 72
Chiltern International Acquires Integrated Development Associates 74
LabCorp May Acquire Pharmaceutical Product Development 75
LabCorp Acquires Covance for USD6.1 Billion 76
BioLegend Acquires Covance Antibody Services from Covance 78
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 79
Covance Acquires Medaxial 80
Gamma-Dynacare Medical Labs Acquires Lab Bio-Medic From Persistence Capital Partners 81
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 82
Gamma-Dynacare Medical Laboratories Acquires MedAxio Insurance Medical Services 83
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 84
Laboratory Corp of America Holdings - Key Competitors 86
Laboratory Corp of America Holdings - Key Employees 87
Laboratory Corp of America Holdings - Locations And Subsidiaries 88
Head Office 88
Other Locations & Subsidiaries 88
Recent Developments 93
Strategy And Business Planning 93
Mar 09, 2018: Covance Forms Immunology & Immunotoxicology Unit Focused on Biologic Drug Development 93
Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK 94
Financial Announcements 95
Feb 06, 2018: LabCorp Reports Net Revenue Of $2.70 Billion In The Fourth Quarter 2017 95
Oct 25, 2017: LabCorp Announces Record Third Quarter Results and Increases 2017 Guidance 98
Jul 26, 2017: LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance 100
Apr 25, 2017: Laboratory Corporation of America Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance 103
Feb 16, 2017: Laboratory Corporation of America Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance 105
Corporate Communications 108
Aug 24, 2017: LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer 108
Jul 18, 2017: LabCorps William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center 109
Mar 29, 2017: LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Companys Two Primary Business Segments 110
Legal and Regulatory 111
Dec 11, 2017: LabCorp Supports American Clinical Laboratory Association Lawsuit on PAMA Final Rule 111
Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation 112
Product News 113
Nov 16, 2017: Cority Enhances Clinical Testing Solution with LabCorp Interface 113
Appendix 114
Methodology 114
About GlobalData 114
Contact Us 114
Disclaimer 114

List Of Tables

List of Tables
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Laboratory Corp of America Holdings, Deals By Therapy Area, 2012 to YTD 2018 11
Laboratory Corp of America Holdings, Medical Devices Deals, 2012 to YTD 2018 12
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
LabCorp Acquires High-Complexity Genomic Lab From Covance 16
LabCorp To Acquire MuirLab Business From John Muir Health 17
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 18
Gamma-Dynacare Medical To Acquire Quebec Operations Of Lifelabs 19
Orig3n Raises USD20 Million in Venture Financing 20
Sera Prognostics Raises USD40 Million in Series C Financing 22
Orig3N Raises USD12.5 Million in Series A Financing 23
Orig3N Raises Funds through Venture Financing 25
Flatiron Health Raises US$130 Million In Series B Financing 26
Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million 27
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 28
Laboratory Corp Enters into Partnership with Capital Health 29
Emulate Enters into Agreement with Covance 30
Sequenom Enters into Agreement with University of Colorado Denver 31
Motif Bio Enters into Agreement with Covance 32
Sequenom Enters into Agreement with University Medical Center Hamburg 33
Sequenom Enters into Agreement with Seoul National University Hospital 34
Sequenom enters into an Agreement with University of California 35
Covance Enters into Co-Development Agreement with Sihuan Pharma 36
Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 37
Covance Enters into Research Agreement with Frenova Renal Research 38
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 39
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 40
Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 41
GNS Healthcare Enters Into Co-Development Agreement With Covance 42
Bayer HealthCare Enters Into Agreement With Covance 43
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 44
LabCorp Enters into Licensing Agreement with Transgenomic 46
Sequenom Completes Public Offering Of Common Stock For US$62 Million 47
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 49
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 51
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 53
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 55
Covance Completes Private Placement Of Notes Due 2025 For US$95 Million 57
Covance Completes Private Placement Of Notes Due 2023 For US$90 Million 58
Covance Completes Private Placement Of Notes Due 2018 For US$15 Million 59
Covance Completes Private Placement Of Notes Due 2020 For US$50 Million 60
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 61
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 63
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 65
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 66
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 68
LabCorp Acquires High-Complexity Genomic Lab From Covance 70
Marken Acquires European Kit Building Operation Facility From LabCorp 71
LabCorp Acquires Chiltern International for USD1.2 Billion 72
Chiltern International Acquires Integrated Development Associates 74
LabCorp May Acquire Pharmaceutical Product Development 75
LabCorp Acquires Covance for USD6.1 Billion 76
BioLegend Acquires Covance Antibody Services from Covance 78
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 79
Covance Acquires Medaxial 80
Gamma-Dynacare Medical Labs Acquires Lab Bio-Medic From Persistence Capital Partners 81
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 82
Gamma-Dynacare Medical Laboratories Acquires MedAxio Insurance Medical Services 83
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 84
Laboratory Corp of America Holdings, Key Competitors 86
Laboratory Corp of America Holdings, Key Employees 87
Laboratory Corp of America Holdings, Other Locations 88
Laboratory Corp of America Holdings, Subsidiaries 89

List Of Figures

List of Figures
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Laboratory Corp of America Holdings, Medical Devices Deals, 2012 to YTD 2018 12

Laboratory Corp of America Holdings (LH) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of

USD 250View Report

Laboratory Corporation of America Holdings - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Laboratory Corporation of America Holdings - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Laboratory Corporation of America Holdings Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

USD 350View Report

Laboratory Corp of America Holdings (LH) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of

USD 250View Report

Laboratory Corporation of America Holdings - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Laboratory Corporation of America Holdings - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Laboratory Corporation of America Holdings Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

USD 350View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :114
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube